Research
Hormonal
New glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been confirmed to reduce weight and preserve kidney function.
Clinicians may consider these new drugs as effective treatment options for managing ORG.
StrongSupportsmedium confidence
Several large clinical trials have confirmed the efficacy and safety of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in reducing weight and preserving kidney function.
Why this rating
The claim is based on findings from large clinical trials.
Source
Obesity-Related Glomerulopathy: Epidemiology, Pathogenesis, and Current Treatments
Xinyu Yang et al. · Integrative Medicine in Nephrology and Andrology · 2024
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →